Log Out

ATyr Pharma, Inc. (NASDAQ:LIFE) Short Interest Up 5.4% in August

Financial News Live · Sep 21, 2022 09:21

aTyr Pharma, Inc. (NASDAQ:LIFE – Get Rating) saw a significant growth in short interest in the month of August. As of August 31st, there was short interest totalling 341,600 shares, a growth of 5.4% from the August 15th total of 324,000 shares. Based on an average trading volume of 131,700 shares, the days-to-cover ratio is presently 2.6 days.

aTyr Pharma Stock Down 3.9 %

LIFE stock opened at $2.93 on Wednesday. The firm's fifty day moving average is $3.49 and its 200 day moving average is $3.76. aTyr Pharma has a 52 week low of $2.60 and a 52 week high of $13.10.

Get aTyr Pharma alerts:

aTyr Pharma (NASDAQ:LIFE – Get Rating) last announced its quarterly earnings data on Monday, August 15th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.01). During the same quarter in the previous year, the company earned ($0.64) earnings per share. On average, research analysts forecast that aTyr Pharma will post -1.81 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. StockNews.com downgraded shares of aTyr Pharma from a "hold" rating to a "sell" rating in a research note on Wednesday, September 14th. HC Wainwright raised their price target on aTyr Pharma from $11.00 to $35.00 and gave the company a "buy" rating in a research report on Thursday, July 21st. Finally, Piper Sandler increased their price objective on aTyr Pharma from $11.00 to $14.00 and gave the company an "overweight" rating in a research report on Monday, August 15th.

Insider Activity

In other news, CEO Sanjay Shukla bought 15,000 shares of the firm's stock in a transaction that occurred on Friday, July 1st. The shares were acquired at an average price of $2.88 per share, with a total value of $43,200.00. Following the acquisition, the chief executive officer now owns 40,798 shares of the company's stock, valued at approximately $117,498.24. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.36% of the stock is owned by company insiders.

Hedge Funds Weigh In On aTyr Pharma

Large investors have recently bought and sold shares of the stock. Raymond James & Associates bought a new position in shares of aTyr Pharma in the fourth quarter worth approximately $184,000. Dimensional Fund Advisors LP raised its stake in shares of aTyr Pharma by 1.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 226,712 shares of the biotechnology company's stock valued at $1,694,000 after acquiring an additional 2,433 shares during the last quarter. Qube Research & Technologies Ltd purchased a new stake in shares of aTyr Pharma during the fourth quarter worth about $87,000. Tikvah Management LLC bought a new stake in shares of aTyr Pharma in the fourth quarter worth about $9,157,000. Finally, GSA Capital Partners LLP purchased a new stake in aTyr Pharma in the 4th quarter worth approximately $439,000. 65.58% of the stock is owned by hedge funds and other institutional investors.

aTyr Pharma Company Profile

(Get Rating)

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.